Navigation Links
GlycoMark Blood Test Included in Global Diabetes Care Guidelines as Emerging Technology
Date:9/25/2007

AMSTERDAM, Netherlands, Sept. 25 /PRNewswire/ -- At the 2007 annual meeting of the European Association for the Study of Diabetes (EASD), the International Diabetes Federation (IDF) issued the new global diabetes guidelines of diabetes care which includes the management of postmeal glucose. These guidelines include the GlycoMark blood test as a new emerging technology to measure postmeal glucose.

In a released statement, the IDF indicated that the guideline emphasizes that people with diabetes should have their blood glucose levels closely monitored after meals in order to optimize diabetes control and reduce the risk of complications, particularly cardiovascular disease. This new approach to managing postmeal glucose will assist clinicians and organizations in developing effective strategies for managing diabetes.

"Diabetes is now recognized as one of the largest epidemics humanity has ever faced and a leading cause of death. It accounts for 3.8 million deaths per year, many of which are related to cardiovascular disease. This new advancement underscores the importance for people with diabetes and their healthcare providers to adopt all possible ways to better manage the disease," said Professor Stephen Colagiuri, Chair of the IDF Task Force on Clinical Guidelines.

The new IDF Guideline recommends that people with diabetes try to keep postmeal blood glucose levels to less than 7.8 mmol/l (140 mg/dl) two hours following a meal. IDF advises SMBG (self-monitoring of blood glucose) because it is the most practical method for measuring postmeal glucose and it allows people with diabetes to obtain "real-time" information about their glucose levels. This information enables people with diabetes and their healthcare providers to make timely adjustments in their treatment regimens to achieve and maintain their blood glucose levels within target. The guideline also includes the 1,5-anhydroglucitol blood test (GlycoMark) and continuous glucose monitoring (CGM) as emerging technologies for measuring postmeal glucose.

About GlycoMark

GlycoMark is an FDA approved test for monitoring intermediate glycemic control by measuring the levels of a monosaccharide 1,5-anhydroglucitol (1,5- AG) in blood. Multiple published studies in peer-reviewed journals have shown that the 1,5-AG test is a specific index of postprandial hyperglycemia (elevated after-meal glucose levels) and short-term glycemic control -- providing a useful complement to A1C testing. GlycoMark is being used in clinical practices nationwide and is available at major reference laboratories including Quest Diagnostics, LabCorp, Esoterix, Mayo Medical Laboratories, ARUP Laboratories, and Specialty Laboratories. The test is also available at most major contract research organizations for pharmaceutical research studies.

In a recent study published in the American Diabetes Association Diabetes Care journal (Dungan et al. Diabetes Care 2006; 29 (6): 1214-1219), it was shown that the GlycoMark 1,5-AG test reflected after-meal glucose levels more robustly than the A1C test. The study also showed that GlycoMark was able to reveal dramatically different after-meal glucose levels in patients with similar A1C levels.

Moreover, studies recently presented at the 67th Annual 2007 Scientific Sessions of the American Diabetes Association and other meetings show that GlycoMark is particularly valuable in detecting underlying treatment effects of agents such as exenatide (Byetta) and pramlintide (Symlin) which were not revealed by the gold standard hemoglobin A1C test. These findings have important implications for patient care and pharmaceutical research as the reduction of after-meal glucose rises is a key objective of diabetes drug therapy.

GlycoMark is being commercialized by a partnership between Toyota Tsusho America (New York, NY), Nippon Kayaku (Tokyo, Japan) and the BioMarker Group (Kannapolis, NC). GlycoMark activities are centered in the North Carolina Research Campus in Kannapolis, North Carolina, a 350-acre life sciences hub started by billionaire David H. Murdock.

More information about GlycoMark may be found at http://www.glycomark.com.

References:

1. Guideline for Management of Postmeal Glucose, International Diabetes

Federation, 20072.

2. Ceriello A, Postprandial Hyperglycemia and Diabetes Complications: Is

it Time to Treat? Diabetes 2005; 54(1):1-7


'/>"/>
SOURCE BioMarker Group
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Recommendations for Treatment of Blood Pressue
2. Blood Cells Capable of Regenerating Liver
3. Infant receives first bloodless liver transplant
4. Spouses and other partners lower blood pressure says new research
5. H2O - a cure for low blood pressure
6. Uncontrolled blood pressure
7. Weight and Blood Pressure
8. Grandmother’s diet in pregnancy can affect grandchildren’s blood sugr
9. Early diagnosis for autism from blood tests may be possible
10. Antibiotic from crab blood indentified
11. Gum disease may be caused by blood clotting gene
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... ... 2017 , ... While EHR data has revolutionized the nursing ... workstation designed to reduce nursing fatigue while enhancing productivity. Based on field experience ... lightweight, highly mobile, multi-functional alternative to the limitations of handheld computing. , Nurses ...
(Date:2/17/2017)... FL (PRWEB) , ... February 17, 2017 , ... ... software tools that allow for the electronic prescribing of controlled and non-controlled substances ... , Ninety percent of pharmacies in the United States now accept electronic prescriptions, ...
(Date:2/17/2017)... VA (PRWEB) , ... February ... ... FDA Device Approval and Reimbursement , **An FDAnews Webinar**, Feb. 22, 2017 ... What are the critical reimbursement questions manufacturers should be asking before selecting ...
(Date:2/17/2017)... Church, VA (PRWEB) , ... February 17, 2017 ... ... Implementing the Steps to Prevent a Warning Letter, **An FDAnews Webinar**, Feb. 23, ... , Do manufacturers distinguish between corrective action (CA) and preventive action (PA)? ...
(Date:2/17/2017)... ... February 17, 2017 , ... Access today ... Exhibition in Orlando, Fla., February 19-23. Visitors to the company’s booth (#1778) will ... used electronic patient signatures solution in healthcare . , Since it first ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... 17, 2017  BioDigital, Inc., creators of the ... their 3D body mapping technology with eClinicalWorks, a ... integration will be used to capture and present ... the human body. BioDigital pilots show using a ... also increasing the precision of clinical annotations compared ...
(Date:2/16/2017)... , Feb. 16, 2017 Absorption Systems, ... and medical devices, is pleased to announce that its ... been selected as a winner of the 2017 Executive ... Magazine and recognizes driven executives for their creative ... ethic. The awards ceremony and celebration is on March ...
(Date:2/16/2017)... DaVita Inc. (NYSE: DVA ) today ... 2016. Net income attributable to DaVita Inc. ... $158 million, or $0.80 per share and $880 million, or ... attributable to DaVita Inc. for the quarter and year ended ... $192 million, or $0.98 per share, and $789 million, or ...
Breaking Medicine Technology: